Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Massachusetts
Clinical trial register · United States · industry-sponsored

Clinical Trials in Massachusetts, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 5309 Florida 4445 Illinois 2491 Georgia 2363 Arizona 2246
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca67 Novartis Pharmaceuticals66 Eli Lilly and Company52 AbbVie39 Bristol-Myers Squibb35
State
California5309 Florida4445 Illinois2491 Georgia2363 Arizona2246
All 51 states
Target enrolment
to

Trials with a site in Massachusetts

1830 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Missouri
2027-11-23
Not yet open
BioSensics
Observational
25
Massachusetts
2027-03-15
Not yet open
HemoSonics LLC
Observational
240
California, Georgia, Massachusetts
2027-03-15
Not yet open
Safety Study of XT-150 in Participants With ALS
NCT06704347Amyotrophic Lateral Sclerosis (ALS)
Xalud Therapeutics, Inc.
Phase 1
8
Arizona, Maryland, Massachusetts, Michigan
2027-03
Not yet open
Nuvation Bio Inc.
Phase 2
40
California, Connecticut, Florida, Indiana, Louisiana, Massachusetts, New Jersey, New York
2027-03
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2027-02-03
Not yet open
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
NCT07240805Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
BioSensics
Observational
60
Maryland, Massachusetts
2027-01-15
Not yet open
Boehringer Ingelheim
Phase 3
270
Arizona, California, Colorado, Kansas, Maryland, Massachusetts, Michigan, Minnesota
2026-12-14
Not yet open
AbbVie
Phase 3
520
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2026-11-30
Not yet open
Bristol-Myers Squibb
Phase 2
80
California, Florida, Illinois, Massachusetts, Oregon, Pennsylvania, Tennessee, Texas
2026-11-30
Recruiting
General Neuro Inc.
Not applicable
60
Massachusetts
2026-11-01
Not yet open
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum
NCT07569367Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Corticobasal Degeneration, Corticobasal Syndrome (CBS)
BioSensics
Observational
60
Maryland, Massachusetts
2026-11-01
Not yet open
IKS04 Regimen in Advanced Solid Tumors That Express CA242
NCT07738939Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
Iksuda Therapeutics Ltd.
Phase 1
120
California, Massachusetts, Tennessee, Texas
2026-11
By invitation
Spine Registration Using 3D-Scanning
NCT06267248Spine Surgery
Advanced Scanners Inc.
Observational
10
Massachusetts
2026-11
Not yet open
Mercy BioAnalytics, Inc.
Not applicable
1,750
Massachusetts, Texas
2026-11
Not yet open
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
NCT07873931Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
Bristol-Myers Squibb
Phase 1
60
California, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New York, Pennsylvania
2026-10-30
Not yet open
Bristol-Myers Squibb
Phase 2
200
Arizona, Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New York
2026-10-30
Not yet open
EMD Serono Research & Development Institute, Inc.
Phase 3
404
Massachusetts
2026-10-15
Not yet open
Hemorai Inc
Not applicable
80
Massachusetts
2026-10-15
Recruiting
Novartis Pharmaceuticals
Phase 3
180
Florida, Massachusetts, Michigan, Ohio, Texas
2026-10-07
Not yet open
Bristol-Myers Squibb
Phase 3
176
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-10-02
Recruiting
Boehringer Ingelheim
Phase 1/2
55
Florida, Massachusetts, New Jersey, New York, Tennessee
2026-10-01
Recruiting
The Impact of Overnight Active Temperature Regulation on Gut Microbiome, Inflammation, and Circadian Rhythm.
NCT07848594Poor Sleep Quality, Gut Microbiome, Gut Health, Inflammation
Eight Sleep Inc.
Not applicable
100
Massachusetts
2026-10
Recruiting
Boston Scientific Corporation
Not applicable
66
California, Florida, Massachusetts, New York, Ohio, Pennsylvania, Washington, West Virginia
2026-10
Not yet open
Real Time Craniotomy Planning Using Mixed Reality
NCT07468370Neurosurgery, Surgical Planning, Brain Tumor Adult, Craniotomy Tumor Removal Surgery
Brainlab AG
Observational
54
Massachusetts
2026-10
Not yet open
Eli Lilly and Company
Phase 2
50
Alabama, California, Florida, Massachusetts, New Jersey, Texas, Virginia, Wisconsin
2026-10
Not yet open
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
NCT07729995Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
DrugLMY-922
Luminary Therapeutics
Phase 1
94
Massachusetts
2026-10
Not yet open
Annexon, Inc.
Phase 3
605
Florida, Maryland, Massachusetts, North Carolina, Oregon
2026-09-30
Recruiting
Biomed Industries, Inc.
Phase 3
210
Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, New York
2026-09-30
Not yet open
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
DrugsPorustobart·Keytruda·Pembrolizumab
Solstice Oncology, Inc.
Phase 2
100
California, Florida, Illinois, Maryland, Massachusetts, New York, Ohio, Tennessee
2026-09-30
Recruiting
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
NCT07725796Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Phase 1
30
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Nebraska, New York
2026-09-28
By invitation
Head Diagnostics
Observational
120
Georgia, Massachusetts
2026-09-28
Recruiting
Acurx Pharmaceuticals Inc.
Phase 2
20
California, Connecticut, Florida, Georgia, Idaho, Illinois, Massachusetts, Michigan
2026-09-25
Recruiting
Akeso
Phase 3
900
Arizona, California, Colorado, Connecticut, Massachusetts, Michigan, New York, Oregon
2026-09-24
Recruiting
Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test
NCT07859852Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia
Deepull Diagnostics S.L.
Observational
1,500
California, Florida, Maryland, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania
2026-09-21
Recruiting
Corvus Pharmaceuticals, Inc.
Phase 1
25
Indiana, Kentucky, Massachusetts, New York, North Dakota, Ohio, Pennsylvania, Tennessee
2026-09-17
Recruiting
Daiichi Sankyo
Phase 1/2
220
California, Colorado, Connecticut, Massachusetts, New York, Oregon, Tennessee, Texas
2026-09-17
Recruiting
Janssen Research & Development, LLC
Phase 2
100
Louisiana, Massachusetts, New York, Tennessee
2026-09-16
By invitation
RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study
NCT07823465Focal Epilepsy, Drug-resistant Focal Epilepsy
NeuroPace
Observational
100
Massachusetts
2026-09-14
Not yet open
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
NCT07807345Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
285
California, Florida, Massachusetts, Oklahoma, Texas, Virginia
2026-09-14
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2026-09-11
Recruiting
Takeda
Phase 3
324
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Montana
2026-09-10
Recruiting
Helios Aesthetics Inc.
Not applicable
50
Florida, Massachusetts, New York, Pennsylvania
2026-09-08
Recruiting
Kyowa Kirin, Inc.
Phase 1
72
California, Florida, Georgia, Iowa, Massachusetts, Missouri, New Jersey, New York
2026-09-02
Recruiting
General Neuro Inc.
Not applicable
60
Massachusetts
2026-09-01
Not yet open
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
NCT07781852Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
Lumina Pharmaceuticals Inc
Early Phase 1
40
Massachusetts, Michigan, New York
2026-09-01
Recruiting
Bayer
Phase 2
360
California, Colorado, Massachusetts, Michigan, Minnesota, North Carolina, Texas
2026-09-01
Not yet open
Worcester HIV Vaccine
Phase 2
126
Massachusetts
2026-09-01
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
80
Florida, Louisiana, Massachusetts, Missouri, Nevada, New Jersey, New York, Ohio
2026-09-01
Not yet open
NeuroRx, Inc.
Phase 2/3
400
Florida, Massachusetts
2026-09-01
Not yet open
Viridian Therapeutics, Inc.
Phase 4
30
California, Florida, Massachusetts, Michigan, Missouri, New Jersey, Texas
2026-09
Recruiting
Regenerative Ocular Immunobiologics LLC
Phase 3
30
California, Florida, Massachusetts
2026-09
Not yet open
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT07325214Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
IMGT Co., Ltd.
Not applicable
360
Massachusetts, Texas, Virginia
2026-09
By invitation
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
NCT07197788Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
Endogenex, Inc.
Not applicable
50
Florida, Massachusetts, New Jersey, North Carolina, Texas
2026-09
Not yet open
Spyre Therapeutics, Inc.
Phase 2
150
California, Indiana, Kentucky, Louisiana, Massachusetts, New York, South Carolina, Texas
2026-09
Recruiting
IDEAYA Biosciences
Phase 3
450
Arizona, California, Massachusetts, Michigan, New York, North Carolina, Ohio, Pennsylvania
2026-09
Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
California, Georgia, Massachusetts, North Carolina, Ohio, Texas
2026-09
Recruiting
Blue Earth Diagnostics
Phase 4
142
California, Georgia, Massachusetts, Missouri, Oregon, Texas
2026-08-31
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
52
Massachusetts, Texas, Washington
2026-08-31
Recruiting
Eli Lilly and Company
Phase 2
120
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2026-08-27
Recruiting
Pfizer
Phase 3
400
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-08-26
Recruiting
Kardigan, Inc.
Phase 3
332
Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts
2026-08-26
Recruiting
Pulnovo Medical, Inc.
Not applicable
750
Arizona, Connecticut, Florida, Louisiana, Massachusetts, Michigan, New York, Ohio
2026-08-21
Recruiting
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
NCT07765446Chemotherapy-induced Peripheral Neuropathy
Sironax USA, Inc.
Phase 2
18
Florida, Maryland, Massachusetts, New Jersey, North Carolina
2026-08-21
Recruiting
PheCheck™ Validation Study
NCT07551921Phenylketonuria (PKU) and Hyperphenylalaninemia
Aptatek BioSciences, Inc
Observational
60
Illinois, Massachusetts
2026-08-20
Recruiting
VarmX B.V.
Phase 3
800
Arizona, California, Colorado, Delaware, Florida, Iowa, Massachusetts, Michigan
2026-08-18
Recruiting
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Maryland, Massachusetts, Texas
2026-08-17
Recruiting
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-08-14
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
156
Massachusetts
2026-08-14
Recruiting
AbbVie
Phase 1
120
Arizona, California, Louisiana, Massachusetts, North Carolina, Tennessee, Texas
2026-08-10
Recruiting
Gilead Sciences
Phase 2
120
Massachusetts, New York
2026-08-07
Recruiting
Eli Lilly and Company
Phase 2
606
Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan
2026-08-07
Recruiting
Cryoablation for Monomorphic Ventricular Tachycardia (VTS)
NCT07650032Ventricular Tachycardia, Sustained, Ventricular Tachycardia, Monomorphic
Adagio Medical
Not applicable
100
Arizona, California, Massachusetts, New York, Pennsylvania, South Carolina, Tennessee, Virginia
2026-08-01
Recruiting
LigaChem Biosciences, Inc.
Phase 1/2
191
Massachusetts, New York, South Carolina, Texas
2026-08
Recruiting
Regeneron Pharmaceuticals
Phase 3
570
Massachusetts
2026-07-31
Recruiting
Evommune, Inc.
Phase 2
330
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New Jersey
2026-07-29
Recruiting
Sanofi
Phase 2
160
California, Florida, Massachusetts, New Jersey, Oregon, Pennsylvania, Texas
2026-07-28
Recruiting
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
NCT07568015Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs, Lateral Hip Pain
DrugTriamcinolone acetate
Brixton Biosciences, Inc.
Not applicable
100
Arizona, Georgia, Louisiana, Massachusetts, New Jersey, Oklahoma, Pennsylvania, Texas
2026-07-27
Recruiting
Autus Valve Continued Access Study (CAS)
NCT07466745Congenital Heart Disease
Edwards Lifesciences
Not applicable
36
California, Colorado, Georgia, Massachusetts, Michigan, New York, North Carolina, Ohio
2026-07-27
Recruiting
Bristol-Myers Squibb
Phase 2
260
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Recruiting
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07601425Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
DrugATV-1601
Atavistik Bio, Inc
Phase 1/2
100
Arizona, Georgia, Indiana, Massachusetts, Minnesota, Utah
2026-07-27
Recruiting
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
NCT07755436Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer
ArriVent BioPharma, Inc.
Phase 1
180
Florida, Massachusetts, Tennessee, Texas, Virginia
2026-07-23
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
Recruiting
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
NCT07286292Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
DrugVorasidenib
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 2
10
California, Illinois, Massachusetts, Minnesota
2026-07-23
Recruiting
Gilead Sciences
Phase 1
112
California, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Nevada, New Jersey
2026-07-22
Recruiting
Freya Biosciences ApS
Phase 2
30
Kansas, Massachusetts, North Carolina, Texas
2026-07-22
Recruiting
Bayer
Observational
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-07-21
Recruiting
Boehringer Ingelheim
Phase 3
35
California, Colorado, Maryland, Massachusetts, Minnesota, Ohio, Pennsylvania
2026-07-21
Recruiting
Novartis Pharmaceuticals
Phase 3
570
Arizona, Florida, Illinois, Massachusetts, Michigan, New Jersey, New York, North Carolina
2026-07-16
Recruiting
AstraZeneca
Phase 3
915
Arkansas, California, Illinois, Massachusetts, Missouri, Nebraska, New York, Ohio
2026-07-16
Recruiting
Jazz Pharmaceuticals
Phase 2
30
California, Louisiana, Massachusetts, New York, Utah
2026-07-16
Recruiting
Boehringer Ingelheim
Phase 3
390
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-07-10
Recruiting
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Observational
500
California, Florida, Illinois, Massachusetts, Oregon, Tennessee
2026-07-08
Recruiting
AstraZeneca
Phase 3
900
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2026-07-06
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
134
California, Colorado, Florida, Iowa, Massachusetts, Michigan, Missouri, New Jersey
2026-07-06
Recruiting
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-07-06
Recruiting
Stealth BioTherapeutics Inc.
Phase 4
48
Massachusetts
2026-07-02
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
272
California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2026-07-01
Recruiting
Prilenia
Phase 3
400
Alabama, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2026-07-01
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
Flare Therapeutics Inc.
Phase 1
60
California, Massachusetts, Michigan, New Jersey, South Carolina, Tennessee, Texas
2026-07-01
Not yet open
Collagen Matrix
Observational
110
Illinois, Massachusetts
2026-07
Recruiting
Hillhurst Biopharmaceuticals, Inc.
Phase 2
36
California, Florida, Massachusetts, Michigan, New York, Washington
2026-06-30
Recruiting
Strand Therapeutics Inc.
Phase 1/2
220
Arizona, Massachusetts, Tennessee
2026-06-30
Recruiting
Neuvosyn Laboratories, LLC
Phase 3
466
California, Colorado, Florida, Idaho, Massachusetts, Nevada, North Carolina, South Carolina
2026-06-30
Recruiting
Nefro Avillion Clinical Development, LLC
Phase 2
120
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Texas, Virginia
2026-06-29
Recruiting
PureTech
Phase 3
1,100
California, Massachusetts, Nevada, Pennsylvania, South Carolina, Tennessee, Texas
2026-06-26
Recruiting
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-06-25
Recruiting
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
DrugCyclobenzaprine
Tonix Pharmaceuticals, Inc.
Phase 2
360
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-06-25
Not yet open
BTL Industries Ltd.
Not applicable
60
Arizona, Florida, Massachusetts
2026-06-24
Recruiting
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
NCT07406633GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour
DrugsKQB198·Imatinib
Kumquat Biosciences Inc.
Phase 2
46
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, New York
2026-06-23
Recruiting
Shockwave Medical, Inc.
Not applicable
185
Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Minnesota
2026-06-22
By invitation
Transcend Therapeutics
Phase 3
300
Arkansas, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Ohio
2026-06-22
Recruiting
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07581184Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
Aktis Oncology, Inc.
Phase 1
138
California, Florida, Kansas, Massachusetts, Michigan, Nebraska
2026-06-17
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
DrugsVS-7375·Cetuximab
Verastem, Inc.
Phase 2
185
California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2026-06-16
Recruiting
Nuevocor Pte. Ltd.
Phase 1/2
21
Alabama, California, Massachusetts, Michigan, Minnesota, Ohio, Texas
2026-06-16
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
NCT07637734Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
California, Florida, Illinois, Kansas, Louisiana, Massachusetts, Minnesota, Nebraska
2026-06-15
Recruiting
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
NCT07632001Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Reprise Biomedical, Inc.
Not applicable
180
Arizona, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma, Texas
2026-06-15
Recruiting
Pfizer
Phase 3
1,200
Alabama, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Massachusetts
2026-06-15
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
132
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Massachusetts, Minnesota
2026-06-12
Active, closed
AstraZeneca
Phase 2
326
California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Missouri, New York
2026-06-11
Recruiting
Neuren Pharmaceuticals Limited
Phase 3
180
Alabama, California, Maryland, Massachusetts, New York, Ohio, Texas
2026-06-08
Recruiting
AstraZeneca
Phase 2
80
Massachusetts, North Carolina
2026-06-04
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Elevar Therapeutics
Phase 2
30
Arizona, Florida, Illinois, Massachusetts, Minnesota, New York, Texas
2026-06-04
Recruiting
Alkeus Pharmaceuticals, Inc.
Phase 3
230
Arizona, Colorado, Florida, Massachusetts, Michigan, Ohio, Pennsylvania, Texas
2026-06-03
Recruiting
Andover Research Eye Institute
Phase 4
60
Massachusetts
2026-06-03
Recruiting
Gilead Sciences
Phase 1
174
Massachusetts, Michigan, New Jersey, New York, Texas
2026-06-02
Recruiting
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
NCT07646587COPD (Chronic Obstructive Pulmonary Disease)
DrugWIN378
Windward Bio
Phase 2
105
California, Florida, Massachusetts, North Carolina, Oregon, Pennsylvania, Texas
2026-06-02
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
California, Florida, Massachusetts, Michigan, Missouri, New York, North Carolina, South Dakota
2026-06-02
Recruiting
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Recruiting
Eli Lilly and Company
Phase 3
252
California, Florida, Idaho, Massachusetts, Michigan, Nevada, Pennsylvania, Utah
2026-06-01
Recruiting
Celldex Therapeutics
Phase 1
12
California, Kansas, Massachusetts, Pennsylvania
2026-06-01
Recruiting
Stryker Endoscopy
Observational
5,000
Florida, Massachusetts
2026-06-01
Not yet open
A Study of CS231295 in Patients With Advanced Solid Tumors
NCT07612488Advance Solid Tumors, Advanced Malignant Solid Tumors
ThalassaX Therapeutics United States Ltd
Phase 1
42
Colorado, Florida, Massachusetts, Tennessee
2026-06
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan
2026-05-28
Recruiting
Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss
NCT07627971GJB2-mediated Hearing Loss, GJB2 Gene Mutation, DFNB1A
Skylark Bio Inc.
Phase 1/2
10
Maryland, Massachusetts, Oklahoma, Pennsylvania
2026-05-28
Recruiting
Pfizer
Phase 4
400
California, Florida, Illinois, Indiana, Massachusetts, Michigan, Minnesota, Mississippi
2026-05-28
Recruiting
Amgen
Phase 3
304
California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts
2026-05-27
Recruiting
Novartis Pharmaceuticals
Phase 1
208
Massachusetts, Texas
2026-05-25
Recruiting
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-05-22
Recruiting
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, Missouri, New York, Ohio
2026-05-21
Recruiting
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
Immunome, Inc.
Phase 1
175
Connecticut, Florida, Massachusetts, Texas
2026-05-21
Recruiting
Exelixis
Phase 2
100
Alabama, Arizona, California, Florida, Illinois, Louisiana, Massachusetts, Missouri
2026-05-21
Recruiting
Alpha Cognition, Inc
Phase 4
150
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-05-20
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
Recruiting
Gilead Sciences
Phase 2
170
Connecticut, Massachusetts, Missouri, South Dakota, Virginia
2026-05-19
Recruiting
Aspeya, Inc.
Phase 2
108
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Missouri, Nevada
2026-05-19
Recruiting
Takeda
Phase 2
222
Arizona, California, Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-05-17
Recruiting
PKP2-ACM Natural History Study
NCT06644742Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Genetic Diseases
Rocket Pharmaceuticals Inc.
Observational
36
Massachusetts, North Carolina
2026-05-15
Recruiting
AbbVie
Phase 1/2
210
California, Colorado, Florida, Massachusetts, Tennessee, Texas
2026-05-15
Recruiting
Draig Therapeutics Ltd
Phase 2
118
Arizona, Arkansas, California, Florida, Georgia, Illinois, Massachusetts, New York
2026-05-14
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Recruiting
Amplifi Vascular, Inc.
Not applicable
160
Massachusetts, Texas
2026-05-12
Recruiting
Alzamend Neuro, Inc.
Phase 1/2
20
Massachusetts
2026-05-11
Recruiting
Incyte Corporation
Phase 1
218
Alabama, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Missouri
2026-05-11
Recruiting
Definium Therapeutics US, Inc.
Phase 3
165
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-05-10
Active, closed
Taysha Gene Therapies, Inc.
Phase 3
4
Alabama, Illinois, Massachusetts
2026-05-08
Recruiting
Computer Guided Microwave Liver Ablation
NCT07226869Hepatocellular Carcinoma (HCC)
NE Scientific INC
Not applicable
84
Massachusetts, New Hampshire
2026-05-08
Recruiting
Regeneron Pharmaceuticals
Phase 2
99
Colorado, Massachusetts, Nebraska, Ohio
2026-05-06
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Arizona, California, Delaware, Florida, Kansas, Massachusetts, Minnesota, Nebraska
2026-05-06
Recruiting
AstraZeneca
Phase 3
420
California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2026-05-05
Recruiting
Pfizer
Phase 3
2,400
Florida, Georgia, Idaho, Illinois, Kentucky, Louisiana, Massachusetts, New York
2026-05-04
Active, closed
Bluejay Diagnostics, Inc.
Observational
450
Florida, Massachusetts, North Carolina, Tennessee, Utah
2026-05-04
Recruiting
Delve Bio, Inc.
Not applicable
400
California, Georgia, Maryland, Massachusetts, Tennessee
2026-05-01
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2026-05
Recruiting
Insulet Corporation
Not applicable
350
California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Massachusetts
2026-04-30
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2026-04-30
Recruiting
Portal Therapeutics, Inc.
Observational
50
Massachusetts, New York, North Carolina, Pennsylvania, Texas
2026-04-30
Recruiting
Descartes-08 in Autoantibody Myositis
NCT07391605Antisynthetase Syndrome
DrugDescartes-08
Cartesian Therapeutics
Phase 2
60
California, Massachusetts, North Carolina, Texas
2026-04-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
District of Columbia, Georgia, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina
2026-04-23
Recruiting
Inhibikase Therapeutics
Phase 3
486
Arizona, California, Colorado, Kansas, Kentucky, Massachusetts, Missouri, New York
2026-04-23
Recruiting
Alkermes, Inc.
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-22
Recruiting
Flo Digital Contraceptive Study
NCT07630064Contraception Use
Flo Health Inc.
Not applicable
3,800
Massachusetts
2026-04-22
Recruiting
Tessera Therapeutics, Inc.
Phase 1/2
72
Florida, Massachusetts, Minnesota, South Carolina, Washington
2026-04-21
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, New York
2026-04-17
Recruiting
Novo Nordisk A/S
Phase 2
270
California, Florida, Idaho, Illinois, Massachusetts, Missouri, North Carolina, Ohio
2026-04-17
Recruiting
Mediar Therapeutics
Phase 2
85
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Minnesota
2026-04-16
Recruiting
Apriligen, Inc.
Phase 1
4
California, Massachusetts
2026-04-16
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
12
Massachusetts, Minnesota
2026-04-16
Recruiting
Blueprint Medicines Corporation
Observational
150
Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah
2026-04-15
Recruiting
Eli Lilly and Company
Phase 2
60
California, Florida, Massachusetts, Michigan, New Hampshire, Texas, Utah
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
AstraZeneca
Phase 2
69
California, Florida, Kentucky, Louisiana, Massachusetts, Missouri, Ohio, Oklahoma
2026-04-14
Recruiting
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
NCT06451757Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
DrugSonlicromanol
Khondrion BV
Phase 3
220
Massachusetts, Ohio, Texas
2026-04-14
Recruiting
BeOne Medicines
Phase 1
84
Massachusetts, Missouri, New Jersey, Texas
2026-04-13
Recruiting
Novo Nordisk A/S
Phase 3
400
Arizona, California, Connecticut, Florida, Georgia, Idaho, Massachusetts, Nevada
2026-04-13
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
NCT07544589Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Dispatch Biotherapeutics
Phase 1
66
California, Florida, Massachusetts, Ohio, Tennessee, Utah
2026-04-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Georgia, Kentucky, Massachusetts, Missouri, New Jersey, New York, Tennessee
2026-04-09
Recruiting
Janssen Research & Development, LLC
Phase 1
170
Connecticut, Florida, Massachusetts, Tennessee, Texas, Virginia
2026-04-09
Recruiting
Medtronic Cardiac Ablation Solutions
Not applicable
400
Alabama, California, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2026-04-08
Recruiting
Pfizer
Phase 3
1,712
Maine, Massachusetts, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia
2026-04-08
Recruiting
Amgen
Phase 1
50
California, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2026-04-08
Recruiting
Diakonos Oncology Corporation
Phase 1/2
35
Alabama, Arizona, California, Massachusetts, New Jersey, North Carolina, Texas
2026-04-06
Recruiting
Alkermes, Inc.
Phase 3
150
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-06
Recruiting
Aktiia SA
Not applicable
164
Massachusetts
2026-04
By invitation
Okami Medical ALPHA Registry
NCT07525518Arterial Bleed, Pulmonary Arteriovenous Malformation, Embolization, Hemorrhage
Okami Medical, Inc.
Observational
500
Colorado, Massachusetts, North Carolina
2026-03-31
Recruiting
MapLight Therapeutics
Phase 2
500
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-03-31
Recruiting
Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)
NCT07357428Amyotrophic Lateral Sclerosis, Neuromuscular Disease, Stroke, Tetraplegia/Tetraparesis
Paradromics
Not applicable
2
California, Massachusetts, Michigan
2026-03-31
By invitation
Behavioral Health Referrals Study
NCT07519083Mental Illness
Outcome Referrals, Inc.
Not applicable
600
Massachusetts
2026-03-30
By invitation
Fulcrum Therapeutics
Phase 2
50
Arkansas, California, Louisiana, Massachusetts, New York, Texas, Virginia
2026-03-30
Recruiting
Pulmair Medical, Inc.
Not applicable
60
California, Illinois, Massachusetts, Wisconsin
2026-03-25
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2
120
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, Missouri
2026-03-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
450
Massachusetts, Michigan, Pennsylvania, Tennessee, Texas, Washington
2026-03-23
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
990
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-03-23
Recruiting
Study in Advanced Solid Tumor Patients
NCT07300943Advanced Solid Tumor
Callio Therapeutics
Phase 1/2
306
Massachusetts, Tennessee, Texas, Utah
2026-03-19
Recruiting
Oruka Therapeutics, Inc.
Phase 2
160
Alabama, Arizona, California, Connecticut, Florida, Illinois, Massachusetts, Michigan
2026-03-19
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
DrugsVisugromab RDE·Opdivo·Lenvatinib·Nivolumab
CatalYm GmbH
Phase 2
104
California, Georgia, Illinois, Massachusetts
2026-03-19
Recruiting
Quoin Pharmaceuticals
Phase 2/3
16
California, Connecticut, Indiana, Massachusetts, Texas
2026-03-19
Recruiting
Novaliq GmbH
Phase 2
20
Arizona, Florida, Massachusetts, New Jersey, Texas, Virginia
2026-03-16
Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
NCT07143019Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm
phenox Inc.
Not applicable
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Massachusetts
2026-03-16
Recruiting
Sanofi
Phase 2/3
526
California, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan, New York
2026-03-13
By invitation
Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07436689Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
800
Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina, South Carolina, Wisconsin
2026-03-13
Active, closed
Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES)
NCT07430371Direct Care Workers, Dementia Caregiver, In-Home Care, Caregiver Social Support
Rendever, Inc.
Not applicable
30
California, Massachusetts, Michigan, Texas
2026-03-11
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc.
Phase 1/2
160
California, Colorado, Massachusetts, Missouri, New York, North Carolina, Ohio, Pennsylvania
2026-03-11
By invitation
Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)
NCT07197775Type 2 Diabetes Mellitus (T2DM), Type2Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
Endogenex, Inc.
Observational
500
Massachusetts, North Carolina, Texas
2026-03-11
Active, closed
Tarsus Pharmaceuticals, Inc.
Phase 2
722
Maryland, Massachusetts, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island
2026-03-09
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Arizona, California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Nevada
2026-03-09
Recruiting
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, NRAS Mutation, NRAS G12D
Relay Therapeutics, Inc.
Phase 1
35
California, Colorado, Massachusetts, Michigan, New York, Tennessee, Virginia
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
272
California, Florida, Massachusetts, New Jersey, New York, Pennsylvania, Texas
2026-03-09
Recruiting
Thryv Therapeutics, Inc.
Phase 2/3
84
Arizona, California, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2026-03-07
Recruiting
Delivering tAN to Reduce HMB: The LUNA Study
NCT07326722Heavy Menstrual Bleeding
Spark Biomedical, Inc.
Not applicable
80
Massachusetts
2026-03-06
By invitation
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
NCT07660640Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
DrugVOY-101
Perceive Biotherapeutics, Inc.
Observational
88
Massachusetts, Texas, Utah
2026-03-03
Active, closed
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Alabama, Arizona, California, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2026-03-03
Recruiting
Monument Therapeutics Limited
Phase 1/2
150
California, Connecticut, Massachusetts, Missouri, New York, North Carolina, Ohio, Oregon
2026-03-03
Recruiting
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
NCT07290244Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Life Biosciences Inc.
Phase 1
18
California, Massachusetts, New York, South Carolina
2026-03-02
Recruiting
Kenvue Brands LLC
Not applicable
250
Massachusetts
2026-02-26
Active, closed
Spryte Medical
Not applicable
67
Florida, Illinois, Massachusetts, New York
2026-02-25
Recruiting
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
NCT07280065PTSD - Post Traumatic Stress Disorder
Senseye, Inc.
Phase 3
1,900
Colorado, Georgia, Idaho, Massachusetts, South Carolina
2026-02-23
Recruiting
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
NCT07148089Catecholaminergic Polymorphic Ventricular Tachycardia
Solid Biosciences Inc.
Phase 1
18
Massachusetts, Minnesota, Ohio, Pennsylvania
2026-02-23
Recruiting
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT07484217Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
DrugSolriamfetol
Axsome Therapeutics, Inc.
Phase 3
508
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2026-02-23
Recruiting
Oruka Therapeutics, Inc.
Phase 2
240
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts
2026-02-23
Recruiting
TearSolutions, Inc.
Phase 2
54
Florida, Indiana, Massachusetts, Minnesota, Missouri, New York
2026-02-19
Recruiting
McGuire Institute
Not applicable
72
California, Connecticut, Massachusetts, Nebraska, Texas, Virginia
2026-02-19
Active, closed
CynosureLutronic
Not applicable
44
Illinois, Massachusetts
2026-02-19
Recruiting
Amplified Sciences Inc
Observational
50
Indiana, Massachusetts, New Jersey
2026-02-17
Recruiting
Kardigan, Inc.
Phase 2/3
332
Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts
2026-02-13
Recruiting
Elion Therapeutics, Inc.
Phase 2
60
Alabama, California, Georgia, Maryland, Massachusetts, Michigan, Missouri, Texas
2026-02-13
Recruiting
I-Mab Biopharma US Limited
Phase 2
180
Arizona, California, Massachusetts
2026-02-11
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
California, Colorado, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2026-02-10
Recruiting
Pfizer
Phase 1/2
224
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2026-02-10
Recruiting
Eli Lilly and Company
Phase 2
450
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-10
Recruiting
AstraZeneca
Phase 2
124
Arizona, California, Kansas, Maryland, Massachusetts, Michigan, New York, North Carolina
2026-02-10
Active, closed
Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer
NCT06654466Hereditary Cancer Syndromes, Clinical Decision Support
Nest Genomics
Not applicable
100
Massachusetts
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts
2026-02-09
Recruiting
Corxel Pharmaceuticals
Phase 2
240
Alabama, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts
2026-02-06
Recruiting
Mannkind Corporation
Phase 2
100
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Oklahoma, Texas
2026-02-04
Recruiting
Balt USA
Not applicable
250
California, Florida, Massachusetts, New York
2026-02-04
Recruiting
Peptilogics
Phase 2/3
240
Florida, Louisiana, Maryland, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2026-02-03
Recruiting
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
NCT07357519Relapsed / Refractory Osteosarcoma
DrugPhase 2
Lantheus Medical Imaging
Phase 1/2
55
California, Massachusetts
2026-02-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
Colorado, Illinois, Maryland, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2026-02-03
Recruiting
Bristol-Myers Squibb
Phase 3
166
California, Florida, Georgia, Illinois, Massachusetts, New York, Ohio, Tennessee
2026-01-29
Recruiting
Alpheus Medical, Inc.
Phase 2
103
Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2026-01-28
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
45
Alabama, California, Florida, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2026-01-26
Recruiting
Takeda
Phase 2
90
Arizona, Arkansas, California, Florida, Massachusetts, Michigan, New Hampshire, New York
2026-01-26
Recruiting
IDEAYA Biosciences
Phase 3
520
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2026-01-25
Active, closed
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Hawaii, Kentucky, Massachusetts, Michigan, New York
2026-01-24
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
California, Illinois, Massachusetts, Michigan, Minnesota, New Jersey, New York, Pennsylvania
2026-01-22
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Arizona, California, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts
2026-01-22
Recruiting
BeOne Medicines
Phase 3
500
California, Colorado, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska
2026-01-22
Recruiting
Generate Biomedicines
Phase 3
786
California, Florida, Kansas, Massachusetts, Michigan, New York, Ohio, Oklahoma
2026-01-20
Recruiting
Regeneron Pharmaceuticals
Phase 1
54
Colorado, Massachusetts, Texas
2026-01-19
Recruiting
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
NCT07114718Congenital Heart Disease, Congenital Heart Disease (CHD)
Starlight Cardiovascular Inc
Not applicable
45
California, Colorado, Massachusetts, Ohio, Pennsylvania, Texas, Washington
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
400
California, District of Columbia, Florida, Georgia, Idaho, Illinois, Massachusetts, Nevada
2026-01-16
Recruiting
Bristol-Myers Squibb
Phase 1
281
Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-01-15
Active, closed
Medtronic Cardiac Ablation Solutions
Not applicable
300
Arkansas, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2026-01-15
Active, closed
Alexion Pharmaceuticals, Inc.
Observational
50
Massachusetts
2026-01-14
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
200
Florida, Massachusetts, New York, Utah, Washington
2026-01-13
Recruiting
Stemline Therapeutics, Inc.
Phase 1
100
Arkansas, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Virginia
2026-01-10
Recruiting
Insmed Gene Therapy LLC
Phase 1
23
California, Maryland, Massachusetts, Missouri, Ohio, Pennsylvania
2026-01-09
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, New Jersey
2026-01-09
Recruiting
Javelin Medical
Not applicable
2,000
Illinois, Massachusetts, New York, Tennessee
2026-01-09
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 1
574
Connecticut, Maryland, Massachusetts, Michigan, New York, Texas, Virginia
2026-01-08
By invitation
SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study
NCT07116668Colorectal Cancer, Stoma - Ileostomy
SafeHeal Inc
Not applicable
108
California, Florida, Massachusetts, New York, North Carolina, Pennsylvania
2026-01-08
Recruiting
Janssen Research & Development, LLC
Phase 3
258
Alabama, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Minnesota, Ohio
2026-01-08
Active, closed
Invivyd, Inc.
Phase 3
1,770
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2026-01-08
Recruiting
The ArtixASCEND Study
NCT07135895Acute Lower Limb Arterial Occlusion
Inari Medical
Not applicable
250
California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan, New Jersey
2026-01-07
Recruiting
Janssen Research & Development, LLC
Phase 3
115
California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts
2026-01-05
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
DrugRadiprodil
GRIN Therapeutics, Inc.
Phase 3
100
California, Colorado, District of Columbia, Florida, Iowa, Massachusetts, New Jersey, New York
2026-01-05
Recruiting
Syndeio Biosciences, Inc
Phase 2
164
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-01-05
Recruiting
Navigator Medicines, Inc.
Phase 2
150
Arizona, Florida, Kentucky, Massachusetts, Mississippi, New Hampshire, New York
2026-01-05
Recruiting
Biogen
Observational
125
Massachusetts
2026-01-02
Recruiting
Acepodia Biotech, Inc.
Phase 1/2
34
Georgia, Massachusetts
2026-01-01
Not yet open
Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis
NCT07224386Myasthenia Gravis, Myasthenia Gravis, Generalized
BioSensics
Observational
50
Massachusetts
2026-01-01
Recruiting
TransMedics
Not applicable
655
California, Florida, Massachusetts, New York, North Carolina, Texas
2026-01
Recruiting
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
NCT07351071Colorectal Anastomosis, Left-sided Colon Resection, Anastomotic Leak, Anastomotic Complication
Medtronic - MITG
Not applicable
137
Connecticut, Florida, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania
2025-12-30
Active, closed
Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems
NCT07296263Intra-axial Tumors, Extra-axial Tumors, Infection/Inflammatory Lesions
Hyperfine
Not applicable
85
Florida, Massachusetts, New York, Pennsylvania, Texas
2025-12-30
Recruiting
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase 2
45
California, Florida, Massachusetts, Ohio, Texas
2025-12-30
Active, closed
Prime Medicine, Inc.
Observational
30
California, Connecticut, Illinois, Massachusetts, Michigan, Texas
2025-12-29
Recruiting
Incyte Corporation
Phase 2
56
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, New York, Virginia
2025-12-29
By invitation
Precision BioSciences, Inc.
Observational
45
Massachusetts
2025-12-25
Recruiting
Diagnosing Epilepsy To EffeCT Change
NCT07110337Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Not applicable
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2025-12-23
Recruiting
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
NCT07110454Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Observational
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2025-12-23
Recruiting
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT07333183Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
20
California, Florida, Illinois, Kansas, Massachusetts, Michigan, New Mexico, North Carolina
2025-12-23
Recruiting
Eli Lilly and Company
Phase 1
41
Connecticut, Massachusetts, Michigan, New York
2025-12-22
Recruiting
Biogen
Observational
300
Massachusetts
2025-12-22
Recruiting
Tyra Biosciences, Inc
Phase 2
230
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2025-12-22
Recruiting
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
NCT06861088Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
DrugIsoquercetin
Quercis Pharma AG
Phase 3
480
California, Florida, Massachusetts
2025-12-19
Recruiting
argenx
Phase 2
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Recruiting
argenx
Phase 2
60
Arkansas, California, Connecticut, Florida, Illinois, Iowa, Maryland, Massachusetts
2025-12-19
Recruiting
argenx
Observational
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-12-19
Recruiting
Merida Biosciences
Phase 1
100
California, Florida, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania, Texas
2025-12-19
Recruiting
Vector Y Therapeutics
Phase 1/2
12
Arizona, California, Florida, Massachusetts, New York, Pennsylvania
2025-12-19
Recruiting
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT07315113EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
DrugsNXP900·Osimertinib
Nuvectis Pharma, Inc.
Phase 1
18
Maryland, Massachusetts, Oregon, Pennsylvania, Texas, Virginia
2025-12-18
Recruiting
Ottimo Pharma Limited
Phase 1/2
170
Connecticut, Massachusetts, Michigan, Texas, Utah
2025-12-17
Recruiting
Draig Therapeutics Ltd
Phase 2
300
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nevada
2025-12-16
Recruiting
Neurocrine Biosciences
Phase 3
560
California, Florida, Georgia, Massachusetts, Mississippi, New Jersey, New York, Texas
2025-12-16
Recruiting
Astellas Gene Therapies
Phase 1/2
9
Illinois, Massachusetts, Oregon, Texas
2025-12-15
Active, closed
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
NCT06323447Diffuse Large B Cell Lymphoma, Multiple Myeloma
Leuko Labs, Inc.
Observational
210
Hawaii, Kentucky, Massachusetts, New Jersey, Texas
2025-12-15
Active, closed
Rubix LS Diabetic Kidney Disease (DKD) Registry Study
NCT07348718Diabetic Kidney Disease (DKD)
Rubix LS
Observational
2,000
Massachusetts
2025-12-15
Recruiting
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy, Sickle Cell Disease
Beam Therapeutics Inc.
Observational
50
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2025-12-15
Recruiting
BeOne Medicines
Phase 1
105
Alabama, California, Connecticut, Maryland, Massachusetts, Texas, Wisconsin
2025-12-11
Recruiting
TuHURA Biosciences, Inc.
Phase 2/3
118
California, Colorado, Florida, Massachusetts, Minnesota, New Jersey, North Carolina, Pennsylvania
2025-12-11
Recruiting
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-12-11
Recruiting
Shionogi
Phase 2
192
California, Florida, Georgia, Massachusetts, Missouri, New York, North Carolina, Ohio
2025-12-11
Recruiting
A Study of NTX-1472 in Social Anxiety Disorder
NCT07323784Social Anxiety Disorder (SAD)
Newleos Therapeutics, Inc.
Phase 2
100
California, Florida, Massachusetts, Nevada, New York, Tennessee, Texas
2025-12-09
Active, closed
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
DrugSAT-3247
Satellos Bioscience, Inc.
Phase 2
51
California, Colorado, Illinois, Massachusetts, Missouri, Ohio, Washington
2025-12-08
Recruiting
Mabylon AG
Phase 1
48
Arkansas, Colorado, Florida, Massachusetts, Michigan, Texas
2025-12-06
Recruiting
Optimize Pattern Recognition Control of Powered Upper Limb Prosthesis
NCT07850544Prosthesis User, Prosthesis, Prosthetic, Upper Limb Amputation
Liberating Technologies, Inc.
Not applicable
32
Illinois, Massachusetts
2025-12-05
Recruiting
Sangamo Therapeutics
Phase 1/2
27
Arizona, Arkansas, California, Maryland, Massachusetts, New Hampshire, New York, North Carolina
2025-12-04
Recruiting
Daiichi Sankyo
Phase 1
60
California, Massachusetts, Michigan, New York, South Carolina, Texas, Virginia, Wisconsin
2025-12-03
Recruiting
Akebia Therapeutics
Phase 2
60
California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-12-03
Recruiting
Sanofi
Phase 2
37
California, District of Columbia, Georgia, Massachusetts, New York, Texas, Washington
2025-12-02
Recruiting
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
Recruiting
Making Connections Thru Music
NCT06079216Dementia, Alzheimer Disease, Vascular Dementia
Hopeful Aging
Not applicable
196
Massachusetts
2025-12-01
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT07284186Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Plexium, Inc.
Phase 1
155
Arizona, California, Massachusetts, Missouri, New York, North Carolina, Ohio, Texas
2025-12-01
Recruiting
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
NCT07197554Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
SEED Therapeutics, Inc.
Phase 1
171
California, Massachusetts, New York, Texas
2025-12-01
Not yet open
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
NCT07169175Amyotrophic Lateral Sclerosis (ALS)
DrugSNUG01
SineuGene Therapeutics Co., Ltd.
Phase 1/2
21
Massachusetts
2025-12-01
Recruiting
Debiopharm International SA
Phase 3
119
California, Illinois, Massachusetts, Missouri, Nevada, New York, Ohio, Oregon
2025-11-26
By invitation
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-11-26
Recruiting
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
NCT07209397Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant)
InMode MD Ltd.
Not applicable
202
California, District of Columbia, Idaho, Illinois, Kansas, Massachusetts, Nebraska, Nevada
2025-11-25
Recruiting
AbbVie
Phase 2
180
Connecticut, Florida, Indiana, Kentucky, Massachusetts, Michigan, Missouri, Ohio
2025-11-25
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
Recruiting
Eli Lilly and Company
Phase 2
400
California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Pennsylvania
2025-11-24
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-11-24
Active, closed
AbbVie
Phase 1
142
Alabama, Arkansas, California, Florida, Illinois, Massachusetts, Minnesota, Missouri
2025-11-24
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-11-22
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
Recruiting
Neurotech Pharmaceuticals
Phase 4
234
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-21
Recruiting
BTL Industries Ltd.
Not applicable
60
Florida, Massachusetts
2025-11-20
Recruiting
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Active, closed
Bayer
Phase 2
60
Alabama, Florida, Georgia, Idaho, Massachusetts, Texas
2025-11-19
Recruiting
Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA
NCT07026877Abdominal Aortic Aneurysms (AAA)
Bolton Medical
Not applicable
20
Colorado, Florida, Massachusetts, Missouri, New York, Texas, Washington
2025-11-18
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
Drug[18F]FAPI-74 PET/CT
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-11-14
Recruiting
A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population
NCT07006831Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function
Devyser Inc.
Observational
400
California, Georgia, Maryland, Massachusetts, Utah
2025-11-14
Recruiting
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.
Phase 2
153
Alabama, California, Colorado, Florida, Massachusetts, Mississippi, Missouri, Nebraska
2025-11-14
Active, closed
Hoffmann-La Roche
Phase 2
193
California, Colorado, Florida, Maryland, Massachusetts, New York, Tennessee, Washington
2025-11-13
Recruiting
AbbVie
Phase 2
400
California, Florida, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Montana
2025-11-13
Recruiting
Neuren Pharmaceuticals Limited
Phase 3
160
Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-12
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-11-12
Recruiting
Eli Lilly and Company
Phase 2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts
2025-11-10
By invitation
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Colorado, Iowa, Massachusetts, New York, North Carolina, Tennessee
2025-11-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
20
Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2025-11-10
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Massachusetts, New York, Texas, Virginia
2025-11-07
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Colorado, Florida, Illinois, Massachusetts, Missouri, New Jersey, New York, Ohio
2025-11-06
Recruiting
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
NCT06888193Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
DrugBimekizumab
UCB Biopharma SRL
Phase 1
20
California, Florida, Massachusetts, North Carolina, Wisconsin
2025-11-05
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada
2025-11-05
Active, closed
CastleVax Inc.
Phase 2
200
Colorado, Massachusetts
2025-11-03
Recruiting
CCM OPEN HF Registry
NCT07112924Heart Failure
Impulse Dynamics
Observational
5,500
Arizona, Florida, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New Hampshire
2025-11-01
Recruiting
SAINT in Postpartum Depression (PPD)
NCT07210255Postpartum Depression (PPD)
Magnus Medical
Not applicable
192
Massachusetts, New York, South Carolina, Texas
2025-11-01
Recruiting
Bausch Health Americas, Inc.
Not applicable
164
California, Illinois, Massachusetts, New York, Texas
2025-10-31
Recruiting
BioNTech SE
Phase 3
558
Arkansas, California, Florida, Illinois, Kentucky, Maine, Maryland, Massachusetts
2025-10-30
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Recruiting
MavriX Bio, LLC
Phase 1/2
12
California, Illinois, Massachusetts
2025-10-29
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
NCT06701656Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugBevacizumab
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-10-28
Recruiting
Oncomatryx Biopharma S.L.
Phase 1
69
Massachusetts
2025-10-28
Recruiting
Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation
NCT07174622Hypertension, Cardiovascular Diseases, Vascular Diseases
Medtronic Vascular
Observational
1,000
Massachusetts
2025-10-28
Recruiting
Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients
NCT07110636Infection, Infections, Bacterial, Infections, Fungal, Infection Viral
Karius, Inc.
Not applicable
2,000
California, Louisiana, Massachusetts, Nebraska, New York
2025-10-27
Recruiting
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
NCT07218887BAG3 Mutation Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
Phase 1/2
6
Alabama, California, Massachusetts, Ohio, Oregon, Pennsylvania, Texas
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Alaska, California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Minnesota
2025-10-24
Recruiting
Sanofi
Phase 3
60
California, Louisiana, Massachusetts, Michigan, Minnesota, New York, Oregon, Utah
2025-10-24
Recruiting
The Short Sleep Study
NCT07567560Short Sleepers
Danisco
Observational
34
Florida, Massachusetts, New York, Texas
2025-10-23
Recruiting
ITF Therapeutics LLC
Observational
300
Arkansas, District of Columbia, Illinois, Massachusetts, New York, North Carolina, Oregon, Washington
2025-10-23
Recruiting
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Phase 2
100
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Massachusetts
2025-10-22
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
Eli Lilly and Company
Phase 2
531
Arizona, California, Colorado, Florida, Illinois, Kentucky, Massachusetts, Nevada
2025-10-22
Recruiting
Regeneron Pharmaceuticals
Phase 2
1,200
Alabama, California, Florida, Georgia, Indiana, Louisiana, Maryland, Massachusetts
2025-10-20
Recruiting
ONWARD Medical, Inc.
Not applicable
60
Arkansas, Colorado, Florida, Georgia, Kentucky, Maryland, Massachusetts, Minnesota
2025-10-17
Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Novartis Pharmaceuticals
Phase 1
116
Iowa, Massachusetts, Michigan, Washington
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Arizona, Arkansas, California, Florida, Illinois, Maryland, Massachusetts, New York
2025-10-16
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
25
Massachusetts, New York, North Carolina
2025-10-16
Recruiting
Long-Term Stability of the Glide Control Strategy
NCT07222085Upper Limb Amputation Above Elbow, Upper Limb Amputation Below Elbow
Infinite Biomedical Technologies
Not applicable
12
Maryland, Massachusetts, North Carolina, South Carolina, Virginia
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington
2025-10-15
Recruiting
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
NCT07172464PFO, PFO - Patent Foramen Ovale, Cryptogenic Stroke, Patent Foramen Ovale
Recross Cardio, Inc.
Not applicable
30
California, Florida, Massachusetts, New York, South Carolina
2025-10-09
Recruiting
Amgen
Phase 1
60
California, Massachusetts, Minnesota, Ohio, Pennsylvania, South Carolina, Tennessee
2025-10-07
Recruiting
Imbria Pharmaceuticals, Inc.
Phase 2
165
California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-10-06
Recruiting
Evaluating the Acceptability, Feasibility and Usability of Various Conversational Data Collection Software
NCT07336537Chronic Pain, Mental Health Disorders, Behavioral Health Challenges, Ecological Momentary Assessment Best Practices
AugMend Health Inc.
Not applicable
100
Massachusetts
2025-10-03
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
355
California, Colorado, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio
2025-10-02
Recruiting
Philips Clinical & Medical Affairs Global
Observational
205
Massachusetts, North Carolina
2025-10-02
Active, closed
Study of COYA 302 for the Treatment of ALS
NCT07161999Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics
Phase 2/3
120
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
283
Arkansas, California, Maryland, Massachusetts, Michigan, New York, Rhode Island, South Carolina
2025-10-01
Recruiting
Vanda Pharmaceuticals
Phase 2
160
California, Massachusetts, North Carolina, Tennessee, Virginia
2025-10
Recruiting
Effects of Myoelectric Channel Count and Targeting for Upper Limb Prosthetic Control
NCT07011420Amputation, Amputation, Traumatic, Amputation, Congenital, Prosthesis User
Liberating Technologies, Inc.
Not applicable
32
Illinois, Massachusetts
2025-10
Recruiting
Wandercraft
Phase 1/2
5
Massachusetts
2025-10
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Arizona, California, Colorado, District of Columbia, Florida, Kentucky, Maryland, Massachusetts
2025-09-30
Recruiting
ModernaTX, Inc.
Phase 1/2
190
Alabama, California, Georgia, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee
2025-09-30
Recruiting
AstraZeneca
Phase 1/2
52
Florida, Massachusetts, Michigan, New York, Rhode Island
2025-09-30
Recruiting
Clinical Course Of Disease In Participants With FA-CM
NCT06865482Friedreich Ataxia, Cardiomyopathy
Lexeo Therapeutics
Observational
65
California, Florida, Indiana, Massachusetts, Minnesota, Missouri, Ohio, Oregon
2025-09-30
Recruiting
Nuvig Therapeutics, Inc.
Phase 2
30
District of Columbia, Massachusetts, North Carolina
2025-09-30
Recruiting
TLN-372 in Advanced KRAS Mutant Solid Tumors
NCT07204340KRAS Mutant Solid Tumors
DrugsCetuximab·Pembrolizumab
Treeline Biosciences, Inc.
Phase 1
270
Alabama, Massachusetts, Michigan, Missouri, New York, Tennessee
2025-09-29
Recruiting
Sanofi
Phase 3
124
California, Florida, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2025-09-26
Recruiting
Daiichi Sankyo
Phase 2/3
630
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-09-26
Recruiting
Advanta VXT and Flixene PMCF Registry
NCT07161583Peripheral Arterial Disease
Atrium Medical Corporation
Observational
1,000
Massachusetts
2025-09-25
Recruiting
A Multi-Center Study Assessing the Safety and Efficacy of the LEGION Medial Stabilized (MS) Insert in Patients Undergoing a Total Knee Arthroplasty (TKA)
NCT07199738Inflammatory Arthritis, Primary Total Knee Arthroplasty Due to Degenerative Joint Disease (Primary Diagnosis of Osteoarthritis), Post-traumatic Arthritis
Smith & Nephew, Inc.
Observational
144
Massachusetts, New York, South Carolina, Wisconsin
2025-09-25
Recruiting
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
NCT06776783Respiratory Distress Syndrome, Pre-term Infants
Aerogen Pharma Limited
Phase 3
520
Arkansas, California, Florida, Indiana, Maryland, Massachusetts, New Jersey, New York
2025-09-24
Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
Pheon Therapeutics
Phase 1
165
California, District of Columbia, Massachusetts, Missouri, North Carolina, Oregon, Tennessee, Texas
2025-09-23
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
DrugSetmelanotide
Rhythm Pharmaceuticals, Inc.
Phase 3
39
Alabama, Colorado, Illinois, Massachusetts, Minnesota, New York, Pennsylvania, Washington
2025-09-23
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
DrugFulvestrant
Terremoto Biosciences Inc.
Phase 1/2
205
California, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina
2025-09-23
Recruiting
Sanofi
Phase 4
218
Alabama, Florida, Georgia, Kansas, Maryland, Massachusetts, North Carolina, Pennsylvania
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, New York, Ohio
2025-09-22
Recruiting
Bristol-Myers Squibb
Observational
300
California, Florida, Illinois, Maryland, Massachusetts, Nebraska, New Jersey, New York
2025-09-22
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
Recruiting
W.L.Gore & Associates
Not applicable
112
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-09-22
Recruiting
Zydus Therapeutics Inc.
Phase 2
240
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Nebraska, North Carolina
2025-09-17
Active, closed
Danisco
Not applicable
174
Florida, Massachusetts, New York
2025-09-17
Recruiting
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Recruiting
US Benchmarking Clinical Study
NCT07215715HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy
eMyosound SAS
Observational
150
Massachusetts
2025-09-16
Recruiting
Teikoku Pharma USA, Inc.
Phase 2
150
California, Florida, Kansas, Massachusetts, New Jersey
2025-09-16
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Kansas, Massachusetts
2025-09-15
Recruiting
Annexon, Inc.
Phase 3
30
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-09-12
Active, closed
MuscleMetrix, LLC
Early Phase 1
3
Massachusetts
2025-09-11
Recruiting
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
125
Massachusetts, North Carolina
2025-09-04
Recruiting
Endoscopic Ultrasound Shear Wave Elastography Study
NCT06592820MASLD, MASH, Fibrosis, Liver, Chronic Liver Disease
Olympus Corporation of the Americas
Observational
300
Massachusetts, Pennsylvania
2025-09-03
Recruiting
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
NCT06919354Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
GentiBio, Inc
Phase 1
16
California, Florida, Massachusetts, New York, North Carolina
2025-09-03
By invitation
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-09-02
Recruiting
Opus Genetics, Inc
Phase 3
580
Arizona, California, Florida, Illinois, Kansas, Massachusetts, North Carolina, Pennsylvania
2025-09-02
Recruiting
AbbVie
Phase 2
140
Alabama, California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-09-02
Not yet open
CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
NCT07057349Metastatic Cancer, Unresectable Solid Tumor
Cytosite Biopharma Inc.
Phase 1
40
Massachusetts
2025-09-01
Recruiting
CREmedical
Observational
90
Arizona, Massachusetts
2025-09-01
Recruiting
Gilead Sciences
Phase 1
476
Massachusetts, Texas, Virginia
2025-08-28
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
153
Delaware, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Ohio, West Virginia
2025-08-21
Recruiting
Nuvation Bio Inc.
Phase 3
180
California, District of Columbia, Florida, Idaho, Louisiana, Massachusetts, Minnesota, New York
2025-08-21
Recruiting
Boston Scientific Corporation
Not applicable
1,616
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-08-21
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
California, Connecticut, Massachusetts, Tennessee, Texas
2025-08-20
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
380
California, Connecticut, Florida, Massachusetts, New York, Ohio, Tennessee, Texas
2025-08-20
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
DrugAZD0120
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
Arizona, California, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2025-08-18
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
California, Colorado, Georgia, Massachusetts, New York, Ohio, Pennsylvania, Texas
2025-08-18
Active, closed
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
NCT07413679Paroxysmal Nocturnal Hemoglobinuria, PNH
DrugDanicopan
Alexion Pharmaceuticals, Inc.
Observational
50
Massachusetts
2025-08-18
Recruiting
Sanofi
Phase 3
90
Arizona, California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, Minnesota
2025-08-18
Recruiting
FIBERGRAFT Aeridyan Posterolateral Fusion Study
NCT07059065Degenerative Spine Disease
DePuy Synthes Products, Inc.
Not applicable
316
California, Illinois, Kentucky, Massachusetts, Pennsylvania
2025-08-15
Recruiting
Nerviano Medical Sciences
Phase 1
10
Illinois, Massachusetts, Tennessee
2025-08-15
Recruiting
BioNTech SE
Phase 1/2
1,438
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York
2025-08-12
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
52
California, Colorado, Illinois, Massachusetts, New York
2025-08-11
Recruiting
AstraZeneca
Phase 3
250
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, Nevada
2025-08-07
Not yet open
Optical Coherence Tomography (OCT) Based Intraoral Scanner
NCT07092592The Focus of the Study is to Evaluate the Efficacy of OCT in Scanning and Reconstructing General Tooth and Gum Anatomy, Tooth Anatomy, Gingival Anatomy
Perceptive Technologies, Inc
Observational
70
Massachusetts
2025-08-07
Recruiting
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
NCT06624644Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
DrugsTemozolomide·Pembrolizumab
Linnaeus Therapeutics, Inc.
Phase 2/3
135
California, Colorado, Florida, Massachusetts, New Mexico, Pennsylvania
2025-08-06
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
Active, closed
Ensoma
Phase 1/2
15
California, Florida, Massachusetts, Minnesota, New York, North Carolina, Utah
2025-08-05
Recruiting
Amivas Inc.
Phase 2
90
Massachusetts, Minnesota
2025-08-01
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
DrugsPalbociclib·Fulvestrant
Bristol-Myers Squibb
Phase 1
234
Alabama, California, Colorado, Massachusetts, Missouri, New Hampshire, New York, Texas
2025-08-01
Not yet open
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)
NCT06948019HSP, Hereditary Spastic Paraplegia, Hereditary Spastic Paraparesis, Hereditary Spastic Paraplegia Type 50
BlackfinBio Ltd
Phase 1/2
5
Massachusetts
2025-08
Not yet open
ImCare Biotech
Observational
1,392
Massachusetts
2025-08
Recruiting
Amgen
Phase 1
434
California, Georgia, Massachusetts, Missouri, North Carolina, Pennsylvania, Tennessee, Texas
2025-07-31
Active, closed
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
DrugATV-1601
Atavistik Bio, Inc
Phase 1
134
California, Florida, Massachusetts, Missouri, Texas
2025-07-29
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
California, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey, New York
2025-07-28
Recruiting
ACTengine® IMA203 Combined With mRNA-4203
NCT06946225Cutaneous Melanoma, Synovial Sarcoma
DrugAnzu-cel
Immatics US, Inc.
Phase 1
15
California, Massachusetts, New York, Texas
2025-07-25
Recruiting
ELEVATE High-Risk PCI Pivotal Study
NCT07001332High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.
Not applicable
290
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-07-25
Recruiting
Celcuity Inc
Phase 3
1,180
Arkansas, California, Colorado, Florida, Kansas, Kentucky, Maryland, Massachusetts
2025-07-24
Active, closed
Windward Bio
Phase 2
136
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska
2025-07-24
Recruiting
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Recruiting
Pfizer
Phase 3
714
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maine, Massachusetts
2025-07-23
Recruiting
Sonoma Biotherapeutics, Inc.
Observational
36
California, Colorado, Illinois, Massachusetts, Minnesota, North Carolina, Texas
2025-07-22
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Alabama, Arizona, California, District of Columbia, Florida, Kentucky, Louisiana, Massachusetts
2025-07-21
Active, closed
Compugen Ltd
Phase 1/2
60
Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina, Ohio, Oklahoma
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
586
California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan, Mississippi
2025-07-21
Active, closed
Oruka Therapeutics, Inc.
Phase 2
80
California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2025-07-18
By invitation
Cybin IRL Limited
Phase 3
468
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-07-18
Recruiting
Daiichi Sankyo
Phase 2
130
Alabama, California, Maryland, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania
2025-07-18
Recruiting
Teleflex
Not applicable
150
California, Kansas, Massachusetts, Michigan, Missouri, New York, Texas, West Virginia
2025-07-18
Recruiting
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
NCT06950385Familial Adenomatous Polyposis (FAP)
DrugERapa
Rapamycin Holdings Inc.
Phase 3
168
California, Connecticut, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri
2025-07-17
Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT07075185Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type
Kelonia Therapeutics, Inc.
Phase 1
70
California, Florida, Georgia, Massachusetts, New Jersey, Oregon
2025-07-16
Recruiting
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2025-07-16
Recruiting
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
NCT06994676High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Crossbow Therapeutics, Inc.
Phase 1
72
California, Florida, Illinois, Massachusetts, Missouri, New York, Pennsylvania, Tennessee
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2025-07-16
Not yet open
Rubix LS
Phase 4
150
Massachusetts
2025-07-16
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Arizona, Colorado, Florida, Louisiana, Massachusetts, Minnesota, New York, Ohio
2025-07-16
Recruiting
Apreo Health, Inc.
Not applicable
250
Alabama, Arizona, California, Florida, Illinois, Kansas, Massachusetts, Michigan
2025-07-15
Active, closed
Bluefin Biomedicine, Inc.
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Louisiana, Massachusetts, Michigan
2025-07-15
Recruiting
Bristol-Myers Squibb
Phase 3
586
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Minnesota
2025-07-14
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Arizona, California, Colorado, Florida, Georgia, Indiana, Louisiana, Massachusetts
2025-07-14
Recruiting
Neurocrine Biosciences
Phase 3
600
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Mississippi
2025-07-11
Recruiting
Abiomed Inc.
Observational
350
Arkansas, California, Florida, Hawaii, Illinois, Massachusetts, Michigan, New Mexico
2025-07-10
Recruiting
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Florida, Louisiana, Maryland, Massachusetts, Michigan
2025-07-10
Recruiting
XyloCor Therapeutics, Inc.
Phase 2
106
Alabama, Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina
2025-07-08
Active, closed
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-07-07
Active, closed
Sanofi
Phase 2
105
California, Florida, Georgia, Iowa, Massachusetts, Michigan, Missouri, New York
2025-07-07
Active, closed
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Recruiting
Radiation Free Study
NCT06549348Aortic Aneurysm
Philips Clinical & Medical Affairs Global
Not applicable
182
Alabama, Massachusetts, Pennsylvania, Texas
2025-07-03
Not yet open
Brainstorm-Cell Therapeutics
Phase 3
200
Arizona, California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Oregon
2025-06-30
Recruiting
Home-Based tDCS Treatment Of Major Depressive Disorder
NCT06976697Major Depressive Disorder (MDD)
Sooma Medical Inc
Not applicable
200
Massachusetts
2025-06-27
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
90
Alabama, Arkansas, California, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-06-27
Recruiting
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
Recruiting
Data Gathering for A10900
NCT07149740Retinal Disease, Healthy, Glaucoma, Corneal Diseases
Optos, PLC
Observational
180
California, Connecticut, Massachusetts, Tennessee
2025-06-26
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
California, Colorado, Florida, Indiana, Kansas, Maryland, Massachusetts, Minnesota
2025-06-26
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
Alabama, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, North Carolina
2025-06-25
Recruiting
Smartphone Services for Stimulant Use Disorder
NCT07092059Stimulant Use Disorder
DynamiCare Health
Not applicable
270
Massachusetts
2025-06-24
Rows per page Showing 1–500 of 1830
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/massachusetts

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,830 of those studies with a site in Massachusetts.

How many clinical trials are recruiting in Massachusetts?

953 of the 1,830 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 43 have not yet opened recruitment, 776 are active but closed to new participants, and 58 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Massachusetts), 1,830 studies
PhaseStudiesRecruitingShare
Phase 338416921%
Phase 235316819.3%
Phase 128917215.8%
Phase 1/228018315.3%
Not applicable23111512.6%
Observational20410011.1%
Phase 2/352282.8%
Phase 434181.9%
Early Phase 1300.2%

Most active sponsors

Lead sponsors with the most studies (Massachusetts)
Lead sponsorStudiesRecruiting
AstraZeneca6729
Novartis Pharmaceuticals6623
Eli Lilly and Company5230
AbbVie3913
Bristol-Myers Squibb3521
Merck Sharp & Dohme LLC3118
Hoffmann-La Roche285
Pfizer2814
Regeneron Pharmaceuticals2620
Janssen Research & Development, LLC2514
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.